

## CURRICULUM VITAE

### Sameem Abedin MD

Assistant Professor  
Department of Medicine  
Division of Hematology and Oncology - Medicine

#### OFFICE ADDRESS:

Froedtert East Clinics  
9200 W Wisconsin Ave  
Milwaukee, WI 53226  
Phone: 414-805-4600  
Email: sabedin@mcw.edu

#### EDUCATION:

2000 - 2004 BA, University of Pennsylvania, Philadelphia, PA  
2005 - 2009 MD, Sidney Kimmel Medical College, Thomas Jefferson Univ, Philadelphia, PA

#### POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

2009 - 2012 Residency in Internal Medicine, University of Pittsburgh, Pittsburgh, PA  
2010 - 2012 Clinical Research Track, CTSI, University of Pittsburgh, Pittsburgh, PA  
2014 - 2017 Fellowship in Hematology/Oncology, Northwestern University, Chicago, IL

#### FACULTY APPOINTMENTS:

2012 - 2014 Clinical Lecturer, Medicine, General Medicine, University of Michigan, Ann Arbor, MI  
07/2017 - Present Assistant Professor, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

#### ADMINISTRATIVE APPOINTMENTS:

02/2021 - Present Phase I DOT Director, Hematologic Malignancies, Medicine, Hematology and Oncology, Medical College of Wisconsin

#### EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:

2016 - 2017 Chief Fellow, Hematology and Oncology, Northwestern University

#### HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:

2009 - 2012 Housestaff Council Representative, Medicine, General Medicine, University of Pittsburgh

#### HOSPITAL STAFF PRIVILEGES:

07/01/2012 - 06/30/2014 Attending Physician, Medicine, Hospital Medicine, University of Michigan, Ann Arbor, MI  
07/15/2017 - Present Attending Physician, Medicine, Hematology and Oncology, Medical College of Wisconsin/Froedtert, Milwaukee, WI

#### SPECIALTY BOARDS AND CERTIFICATION:

<u>Board Certified</u>	<u>Issue Date</u>	<u>Expiration</u>
Internal Medicine	2012	2022
Medical Oncology	2017	2027

<u>Licensure</u>	<u>Number</u>	<u>Issue Date</u>	<u>Expiration</u>
PA Medical License		2009	2012
MI Medical License		2012	2014
IL Medical License		2014	2017
WI Medical License		2017	2022

#### **AWARDS AND HONORS:**

2008 - 2009 Hobart Amory Hare Medical Honor Society, Sidney Kimmel Medical College  
2009 Foerderer Award for International Study, Sidney Kimmel Medical College  
2016 ASBMT Clinical Research Scholar, ASBMT  
2017 - 2019 CTSI Clinical Research Scholar, CTSI of Southeast Wisconsin  
2018 - 2019 Faculty Development Award, Medical College of Wisconsin  
2019 Moderator, American Society of Hematology Annual Meeting, Acute Myeloid Leukemia: Clinical Studies  
2019 Top Patient Experience Award  
2020 Scientific Discussant, American Society of Clinical Oncology Annual Meeting, Novel Treatments in Acute Leukemia  
2020 - Present Moderator, American Society of Hematology Annual Meeting, Acute Myeloid Leukemia: Clinical Studies

#### **MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:**

2014 - Present American Society of Hematology  
2014 - Present American Society of Clinical Oncology  
2016 - Present American Society for Blood and Marrow Transplantation

#### **EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:**

Journal Review  
2016 - Present Reviewer, Leukemia and Lymphoma  
2019 - Present Biology of Blood and Marrow Transplantation  
2019 - Present Blood Advances  
2019 - Present PLOS One

#### **NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:**

10/2018 ABIM Oncology Standard Setting Meeting, American Board of Internal Medicine  
2019 Abstract Reviewer, AML clinical studies, American Society of Hematology  
2019 - Present Member, Biomarker Committee, BMT-CTN

#### **RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:**

##### **Active**

##### **Peer Review**

Title: IIT Abedin Neihulizumab: A Phase I Trial of Neihulizumab for Standard risk acute GVHD  
Source: AltruBio Inc.  
Role: Principal Investigator  
Dates: 12/2020 - Present  
Direct Funds: \$150,100

Title: IIT Abedin: A Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)  
Source: Pfizer Pharmaceutical and Helsinn Pharmaceutical

Role: Principal Investigator  
Direct Funds: \$165,000 (Pfizer and Helsinn)

Title: IIT-Abedin: A Phase I Study of Lintuzumab-Ac225 in Combination with Clag-M Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Source: Actinium Pharmaceuticals, Inc.  
Role: Principal Investigator  
Direct Funds: \$180,014

**Non-Peer Review**

Title: A Phase I/II study to investigate the safety and clinical activity of GSK3326595 and other agents in subjects with myelodysplastic syndrome and acute myeloid leukemia

Role: Institutional PI  
Dates: 2019 - Present

Title: A Phase I, Dose Escalation and Expansion Study of Engineered Donor Grafts Derived from Mobilized Peripheral Blood (Orcagraft) With Single Agent Graft-Versus-Host Disease Prophylaxis, In Recipients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Role: Institutional PI  
Dates: 2019 - Present

Title: Alliance-A041702: A Randomized Phase III Study of Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients ( $\geq 70$  years of Age) with CLL

Role: Institutional PI  
Dates: 04/2020 - Present

Title: MEI-522-001: A Phase I, Open-label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B Cell Malignancies or Acute Myeloid Leukemia After Failure of Prior Standard Therapies

Role: Institutional PI  
Dates: 2020 - Present

Title: S1612: Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Role: Institutional PI

Title: Ruxolitinib + Allogeneic Stem Cell Transplantation in AML  
Source: DFCI  
Role: Institutional PI

Title: ABGENOMICS-2017-002-01; A phase I study of Neihulizumab (AbGn-168H) in patients with steroid-refractory acute graft-versus-host disease (sr-aGvHD)  
Role: Institutional PI

Title: A Study of Safety and Tolerability of ABBV-621 in Participants with Previously Treated Solid Tumors and Hematologic Malignancies  
Source: AbbVie  
Role: Institutional PI

**Prior**

**Non-Peer Review**

Title: NLA101 in Adults Receiving High Dose Chemotherapy for AML (LAUNCH)  
Role: Institutional PI

**INVITED LECTURES/WORKSHOPS/PRESENTATIONS:**

**Local**

Aspirin and its Role in Colorectal Cancer Prevention, University of Pittsburgh Medicine Grand Rounds, Pittsburgh, PA, 2012  
Cyclin Dependent Kinase 9 Inhibition as a Therapeutic Target in AML, Robert H Lurie Comprehensive Cancer Center Grand Rounds, Chicago, IL, 2016

**Regional**

Transplants 101: Autologous and Allogeneic, LLS Blood Cancer Conference 2018, Milwaukee, WI, 09/22/2018  
AML in 2019: Approaching the Vision of Precision Medicine, 8th Annual Heme Malignancy Symposium, 02/2019  
What's New In Acute Myeloid Leukemia, MCW Department of Medicine Grand Rounds, 11/01/2019

**National**

Understanding Stem Cell Transplantation and GVHD, Lymphoma Research Foundation, 11/2020

**International**

A Phase I Study of Lintuzumab-Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML, ASH Annual Meeting, 12/05/2020

**COMMITTEE SERVICE:**

**Medical College of Wisconsin**

12/2017 - Present Co-Chair, GVHD Scoring Committee, Hematology/Oncology  
02/2018 - Present Member, Clinical Cancer Genomics Review Committee, Hematology/Oncology  
03/2018 - Present Member, Institutional Review Board  
2019 Co-Director, Organizing Committee, 9th Annual Controversies in Hematologic Malignancies

## **EXTRAMURAL TEACHING:**

### **Medical Student Education**

03/2016 Northwestern University, M2 Spirituality Small Group Discussion Leader

03/2017 Northwestern University, Malignant Hematology Small Group Discussion Leader

## **BIBLIOGRAPHY**

### **Refereed Journal Publications/Original Papers**

1. Abedin S, Michel JJ, Lemster B, Vallejo AN. Diversity of NKR expression in aging T cells and in T cells of the aged: the new frontier into the exploration of protective immunity in the elderly. *Exp Gerontol*. 2005 Jul;40(7):537-48.
2. Shaikh N, Abedin S, Docimo SG. Can ultrasonography or uroflowmetry predict which children with voiding dysfunction will have recurrent urinary tract infections? *J Urol*. 2005 Oct;174(4 Pt 2):1620-2; discussion 1622.
3. Seo HS, Abedin S, Kamp D, Wilson DN, Nierhaus KH, Cooperman BS. EF-G-dependent GTPase on the ribosome. conformational change and fusidic acid inhibition. *Biochemistry*. 2006 Feb 28;45(8):2504-14.
4. Dvergsten JA, Mueller RG, Griffin P, Abedin S, Pishko A, Michel JJ, Rosenkranz ME, Reed AM, Kietz DA, Vallejo AN. Premature cell senescence and T cell receptor-independent activation of CD8+ T cells in juvenile idiopathic arthritis. *Arthritis Rheum*. 2013 Aug;65(8):2201-10. PMID: PMC3729743
5. Abedin S, Peres E, Levine JE, Choi S, Yanik G, Couriel DR. Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation. *Biol Blood Marrow Transplant*. 2014 Dec;20(12):2062-6. PMID: PMC4291068
6. Abedin S, Yanik GA, Braun T, Pawarode A, Magenau J, Goldstein SC, Levine JE, Kitko CL, Couriel DR. Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung. *Biol Blood Marrow Transplant*. 2015 Jun;21(6):1127-31. PMID: PMC4970454
7. Abedin S, Platanius LC. Whole-exome sequencing for relapse prediction in patients discontinuing TKI treatment in chronic myeloid leukemia. *Leuk Lymphoma*. 2016 Jul;57(7):1503-4.
8. Kosciuzuk EM, Saleiro D, Kroczyńska B, Beauchamp EM, Eckerdt F, Blyth GT, Abedin SM, Giles FJ, Altman JK, Platanius LC. Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo. *Blood*. 2016 Jul 21;128(3):410-4. PMID: PMC4957163
9. Abedin SM, Boddy CS, Munshi HG. BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects. *Onco Targets Ther*. 2016;9:5943-5953. PMID: PMC5047722
10. Abedin S, Altman JK. Acute promyelocytic leukemia: preventing early complications and late toxicities. *Hematology Am Soc Hematol Educ Program*. 2016 Dec 02;2016(1):10-15. PMID: PMC6142484
11. Abedin S, Platanius LC. PD1 and PDL1 upregulation and survival after decitabine treatment in lower risk MDS. *Leuk Lymphoma*. 2017 Apr;58(4):764-765.
12. Bell JB, Abedin S, Platanius LC. Circulating microRNAs: promising biomarkers in aplastic anemia. *Haematologica*. 2017 Jan;102(1):1-2. PMID: PMC5210225
13. Abedin S, Platanius LC. Implications of high EVI1 expression in high-risk myelodysplastic syndromes. *Leuk Lymphoma*. 2018 Dec;59(12):2765-2766.
14. Raj RV, Abedin SM, Atallah E. Incorporating newer agents in the treatment of acute myeloid leukemia. *Leuk Res*. 2018 Nov;74:113-120.
15. Guru Murthy GS, Pondaiah SK, Abedin S, Atallah E. Incidence and survival of T-cell acute lymphoblastic leukemia in the United States. *Leuk Lymphoma*. 2019 May;60(5):1171-1178.
16. Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. *Biol Blood Marrow Transplant*. 2019 Apr;25(4):827-833.
17. Beauchamp EM, Abedin SM, Radecki SG, Fischietti M, Arslan AD, Blyth GT, Yang A, Lantz C, Nelson A, Goo YA, Akpan I, Eklund EA, Frankfurt O, Fish EN, Thomas PM, Altman JK, Platanius LC. Identification and targeting of novel CDK9 complexes in acute myeloid leukemia. *Blood*. 2019 Mar 14;133(11):1171-1185. PMID: PMC6418475
18. Patel AB, Pettijohn EM, Abedin SM, Raps E, Deininger MW. Leukemoid reaction in chronic

- myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations. *Blood Adv.* 2019 Apr 09;3(7):952-955. PMID: PMC6457233
19. Guru Murthy GS, Abedin S. Myeloid malignancies after treatment for solid tumours. *Best Pract Res Clin Haematol.* 2019 Mar;32(1):40-46.
  20. Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, Hari PN, Hamadani M. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant.* 2019 Aug;25(8):1689-1694.
  21. Abedin SM, Platanius LC. Natural killer cell activity and survival after azacitidine treatment in high-risk MDS. *Leuk Lymphoma.* 2019 Oct;60(10):2343-2344.
  22. Kosciuczuk EM, Kar AK, Blyth GT, Fischietti M, Abedin S, Mina AA, Siliezar R, Rzymiski T, Brzozka K, Eklund EA, Beauchamp EM, Eckerdt F, Saleiro D, Platanius LC. Inhibitory effects of SEL201 in acute myeloid leukemia. *Oncotarget.* 2019 Dec 24;10(67):7112-7121. PMID: PMC6935253
  23. Kosciuczuk EM, Kar AK, Blyth GT, Fischietti M, Abedin S, Mina AA, Siliezar R, Rzymiski T, Brzozka K, Eklund EA, Beauchamp EM, Eckerdt F, Saleiro D, Platanius LC. Inhibitory effects of SEL201 in acute myeloid leukemia *Oncotarget.* 2019;10(67):7112-7121.
  24. Guru Murthy GS, Szabo A, Michaelis L, Carlson KS, Runaas L, Abedin S, Atallah E. Improving Outcomes of Acute Promyelocytic Leukemia in the Current Era: Analysis of the SEER Database. *J Natl Compr Canc Netw.* 2020 Feb;18(2):169-175.
  25. Abedin SM, Hamadani M. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease. *Expert Opin Investig Drugs.* 2020 May;29(5):423-427.
  26. George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, Atallah E, Baumann-Kreuziger L. Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase—A real world study *Leukemia Research.* July 2020;94.
  27. Abid MB, Hamadani M, Szabo A, Hari PN, Graham MB, Frank MO, Collier WS, Abedin S, Jerkins JH, Pasquini MC, Runaas L, Shah NN, Chhabra S. Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. *Biol Blood Marrow Transplant.* 2020 Sep;26(9):1670-1678.
  28. George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, Atallah E, Baumann-Kreuziger L. Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study. *Leuk Res.* 2020 Jul;94:106368.
  29. Chhabra S, Abedin S, Graham MB, Ferrer Marrero TM, Hari PN, Shaw BE. Letter to the Editor Regarding "Diagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantation". *Biol Blood Marrow Transplant.* 2020 Sep;26(9):e241-e242. PMID: PMC7309826
  30. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant.* 2020 Oct;26(10):1876-1885. PMID: PMC7571859
  31. Mushtaq MU, Harrington AM, Chaudhary SG, Michaelis LC, Carlson KB, Abedin S, Runass L, Callander NS, Fallon MJ, Juckett M, Hall AC, Hematti P, Mattison RJ, Atallah EL, Guru Murthy GS. Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia. *Leuk Lymphoma.* 2021 Jan;62(1):158-166.
  32. Abid MB, Chhabra S, Buchan B, Graham MB, Abedin S, Thapa B, D'Souza A, George B, Hamadani M. Bronchoalveolar lavage-based COVID-19 testing in patients with cancer. *Hematol Oncol Stem Cell Ther.* 2021 Mar;14(1):65-70. PMID: PMC7543702
  33. Abedin S, Hamadani M. Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease. *J Exp Pharmacol.* 2020;12:549-557. PMID: PMC7705269
  34. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M. Corrigendum to 'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation' [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885] (Biology of Blood and Marrow Transplantation (2020) 26/10(1876-1885) (S1083879120304146), (10.1016/j.bbmt.2020.07.005)) *Transplantation and Cellular Therapy.* 2021.

35. Abedin S, Rashid N, Schroeder M, Romee R, Nauffal M, Alhaj Moustafa M, Kharfan-Dabaja MA, Palmer J, Hogan W, Hefazi M, Larson S, Holtan S, DeFilipp Z, Jayani R, Dholaria B, Pidala J, Khimani F, Grunwald MR, Butler C, Hamadani M. Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis. *Br J Haematol.* 2021 Nov;195(3):429-432. PMID: PMC9293486
36. Dhakal B, Abedin S, Fenske T, Chhabra S, Ledebner N, Hari P, Hamadani M. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. *Blood.* 2021 Oct 07;138(14):1278-1281. PMID: PMC8332674
37. Kunte S, Rybicki L, Viswabandya A, Tamari R, Bashey A, Keyzner A, Iqbal M, Grunwald MR, Dholaria B, Elmariah H, Ozga M, Singh A, Abedin S, DeZern AE, Jones RJ, Gupta V, Gerds AT, Jain T. Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. *Leukemia.* 2022 Mar;36(3):856-864.
38. Abid MB, Rubin M, Ledebner N, Szabo A, Longo W, Mohan M, Shah NN, Fenske TS, Abedin S, Runaas L, D'Souza A, Chhabra S, Dhakal B, Hamadani M. Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients. *Cancer Cell.* 2022 Apr 11;40(4):340-342. PMID: PMC8864440
39. Mohan M, Nagavally S, Shah N NN, Michaelis L, Chhabra S, Souza AD, Abedin S, Runaas L, Guru Murthy GS, Longo W, Hamadani M, Dhakal B, Hari P, Fenske TS. Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. *Clin Lymphoma Myeloma Leuk.* 2022 Jul;22(7):e495-e497. PMID: PMC8767926
40. Corrao K, Rezwan S, Atallah E, Michaelis LC, Runaas L, Harrington AM, Abedin S. Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome. *Leuk Res Rep.* 2022;17:100329. PMID: PMC9150024
41. Abedin SM, Badar T, Gauger K, Michaelis LC, Runaas L, Carlson KS, Murthy GG, Atallah E. Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia. *Leuk Res.* 2022 Dec;123:106984.
42. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M. Corrigendum to 'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation' [*Biology of Blood and Marrow Transplantation* 26/10 (2020) 1876-1885]. *Transplant Cell Ther.* 2022 Oct;28(10):717.

### **Abstracts**

1. Rios, J, Abedin, S, Rosenzweig, P, Brufsky, A. Methallothionein expression and outcome in patients with metastatic breast cancer (MBC). Poster presented at: ASCO Annual Meeting 2012; Chicago, IL
2. Abedin, S, Yanik, G, Magenau, J, Pawarode, A, Goldstein, S, Kitko, C, White, E, Couriel, D. The Use of Early Spirometric Changes and IGF-1 Levels for the Early Detection of Patients at Risk for BOS. Poster presented at: BMT Tandem Meetings 2013; Salt Lake City, UT
3. Abedin, S, Kruse, ML et al. HER2 copy number on FISH as a predictor of disease severity in HER2-negative Breast Cancer. Poster presented at: SABC 2013; San Antonio, TX
4. Vostina, E, Singavi, AK, Jacquart A, Runaas L, Atallah, EL, Michaelis LC, Abedin, S. Systematic Screening for Familial Leukemia Based on Somatic Genomic Profiling Results. Presented at: ASH Annual Meeting 2018; San Diego, CA
5. Mushtaq MU, Chaudhary SG, Michaelis LC, Carlson K, Abedin S, Runaas L, Fallon MJ, Harrington AM, Juckett M, Hall AC, Mattison RJ, Atallah EL, and Guru Murthy GS. Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia. Poster presented at: ASH Annual Meeting 2018; San Diego, CA
6. Corrao KM, Michaelis LC, Baumann Kreuziger L, Carlson K, Abedin S, Malosh E, Atkinson D, Shan W, Quinet S, Umpierrez De Reguero A, Julie D, Trembl A, Runaas L, and Atallah EL. 40 Is the New 50: Reducing the Need for Platelet Transfusions Prior to Lumbar Puncture in Patients with Hematologic Malignancies. Poster presented at: ASH Annual Meeting 2018; San Diego, CA
7. Abedin S, Guru Murthy GS, Runaas L, et al. Lintuzumab Ac-225 in Combination with CLAG-M in Relapsed/Refractory AML: Interim Results of a Phase I Study. Poster presented at: ASH Annual Meeting 2019; Orlando, FL
8. Watts J, Bradley T, Thomassen A, Brunner A, Minden M, Papadantonakis N, Abedin S, et al. A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5

inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia.  
Poster Presented at: ASH Annual Meeting 2019; Orlando, FL

9. Corrao K, Harrington AM, Kroft SH, Michaelis LC, Carlson KS, Runaas L, Atallah E, Abedin S. The Prognostic Significance of Blast Aberrancies By Flow Cytometry in Low/Int Risk MDS. *Blood*. 2019 Oct; 134: Supplement 1: 5430
10. Abedin S, Hamadani M, Holtan SG, et al. Neihulizumab (ABGN-168H) In Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-AGVHD): Preliminary Results of a Phase I Study: Poster presented at: EHA 2020